IHS Chemical Week

People & Business :: M&A

Glaxo and Novartis announce major three-part business transaction

12:27 PM MDT | April 22, 2014 | Natasha Alperowicz

GlaxoSmithKline (GSK) today announced a major, three-part transaction with Novartis involving its consumer health-care, vaccines, and oncology businesses. GSK and Novartis, as part of the transaction, will create a new, world-leading consumer health-care business with 2013 pro forma revenues of £6.5 billion ($10.9 billion). GSK will have a 63.5% equity interest in the joint venture. Meanwhile, GSK will acquire Novartis’s global vaccines business, excluding influenza vaccines, for an initial cash consideration of $5.25 billion and subsequent potential...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa